0
Abstract: Poster Presentations |

HIGH SATISFACTION WITH FLUTICASONE PROPIONATE/SALMETEROL VIA DISKUS REPORTED DURING EXPERIENCE PROGRAM IN PATIENTS WITH COPD FREE TO VIEW

Stuart Stoloff, MD*; Steven Samuels, MD; Sidney Braman, MD; Christy Brown, PharmD; Donna Kerney, PhD; Michael Cicale, MD
Author and Funding Information

University of Nevada School of Medicine, Reno, NV


Chest


Chest. 2005;128(4_MeetingAbstracts):260S. doi:10.1378/chest.128.4_MeetingAbstracts.260S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  An initial experience program was conducted in patients with COPD to collect patient reported feedback about newly initiated therapy with fluticasone propionate/salmeterol 250/50 (FSC).

METHODS:  Patients completed 2 surveys; one at baseline (before initiating therapy with FSC 250/50) and one targeted for 30 days after starting therapy with FSC 250/50). The first survey collected patient demographics, duration of COPD diagnosis, smoking history, and satisfaction with prior treatment. The second survey assessed patient perceived impact of FSC 250/50 on breathing, and convenience and satisfaction with FSC therapy.

RESULTS:  A total of 973 patients completed both surveys. Completers were mostly female (62%), and 87% were ≥ 45 years of age. Two-thirds of the completers had been diagnosed with COPD for ≥ 1 year. At baseline, 58% of the population used prescription medications prior to starting FSC 250/50. The most common medications were ipratropium/albuterol (37%) and salmeterol (27%). Patients reported satisfaction with their prior therapy (5.52 on a 9 point scale), but 22% of patients were quite dissatisfied (1-3 on a 9 point scale). The second survey, completed an average of 51 days after starting FSC 250/50, showed that patients perceived improvement in their breathing overall (6.82 on a 9 point scale) and had a high level of satisfaction with FSC 250/50 (7.76 on a 9 point scale). Less than 4% of patients were quite dissatisfied (<3 on a 9 point scale). FSC 250/50 was regarded as a very convenient medication (8.12 on a 9 point scale).

CONCLUSION:  Patients with COPD reported a high level of satisfaction with their treatment an average of 51 days after initiating therapy with FSC 250/50.

CLINICAL IMPLICATIONS:  High patient satisfaction with therapy may encourage increased compliance with therapy and therefore may result in improved outcomes.

DISCLOSURE:  Stuart Stoloff, Grant monies (from industry related sources) Received research grants from GlaxoSmithKline; Consultant fee, speaker bureau, advisory committee, etc. Received consultant fees from GlaxoSmithKline and serve on speaker bureau and advisory board for GlaxoSmithKline

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543